ChemicalBook > CAS DataBase List > Naloxone

Naloxone

Product Name
Naloxone
CAS No.
465-65-6
Chemical Name
Naloxone
Synonyms
Naloxone impurity;C07252;NALOXONE;NSC 70413;l-naloxone;Naloxone API;-bcd)furanone;Naloxone Base;,5-bcd)furanone;Naloxone (125 mg)
CBNumber
CB5728727
Molecular Formula
C19H21NO4
Formula Weight
327.37
MOL File
465-65-6.mol
More
Less

Naloxone Property

Melting point:
184° (Lewenstein), 177-178° (Sankyo Co.)
alpha 
D20 -194.5° (c = 0.93 in CHCl3)
Boiling point:
465.27°C (rough estimate)
Density 
1.2223 (rough estimate)
refractive index 
1.5000 (estimate)
Flash point:
9℃
storage temp. 
2-8°C
solubility 
Chloroform (Slightly, Heated, Sonicated), DMSO (Slightly), Methanol (Slightly),
form 
Solid
pka
pKa 7.94/7.82(H2O,t =20/37,I<0.01) (Uncertain)
color 
White to Off-White
InChIKey
UZHSEJADLWPNLE-GRGSLBFTSA-N
EPA Substance Registry System
Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5.alpha.)- (465-65-6)
More
Less

Safety

Hazard Codes 
F,T
Risk Statements 
11-23/24/25-39/23/24/25
Safety Statements 
7-16-36/37-45
RIDADR 
UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany 
3
HS Code 
2939190000
Hazardous Substances Data
465-65-6(Hazardous Substances Data)
Toxicity
An opiate antagonist devoid of agonist activity except for mild, specific effects at very high doses. Naloxone displays a high affinity for the μ-opioid receptor, a lesser affinity for the kopioid receptor and has some affinity for δ-opioid receptor subtypes. Naloxone produces a rapid and profound reversal of the effects of opioid administration (e.g., 1 mg, i.v., blocks the effects of 25 mg of heroin). Naloxone also antagonizes the analgesia induced by placebo, acupuncture, and stress, and in animals the hypotension due to hypovolemia or spinal cord injury. Naloxone has a short half-life (about 1 h in plasma) and is not administered orally because of rapid, “first-pass” metabolism.
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
N-004
Product name
Naloxone solution
Purity
1.0?mg/mL in methanol, ampule of 1?mL, certified reference material, Cerilliant?
Packaging
1mL
Price
$38.1
Updated
2024/03/01
Sigma-Aldrich
Product number
1453005
Product name
Naloxone
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
200mg
Price
$358
Updated
2024/03/01
TRC
Product number
N284995
Product name
Naloxone
Packaging
5mg
Price
$90
Updated
2021/12/16
American Custom Chemicals Corporation
Product number
API0003490
Product name
N-ALLYLNOROXYMORPHONE
Purity
95.00%
Packaging
1G
Price
$945.95
Updated
2021/12/16
Chemtos
Product number
SL-N-00630
Product name
Naloxone-d50.1mg/ml
Packaging
0.1mg
Price
$250
Updated
2021/12/16
More
Less

Naloxone Chemical Properties,Usage,Production

Description

It is worth mentioning that N-allylic substitution in a number of morphine derivatives, as a rule, leads to antagonistic properties. Naloxone is a few times stronger than nalorphine as an antagonist. It blocks opiate receptors. It eliminates central and peripheral action of opioids, including respiratory depression. Naloxone is used upon overdose of narcotic analgesics.

Originator

Narcan,Du Pont,US,1971

Uses

Naloxone is a specific opioid antagonist. Narcotic antagonist.

Uses

antineoplastic

Definition

ChEBI: A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an all l group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.

Manufacturing Process

10 grams of 14-hydroxydihydromorphinone (oxymorphone) was converted into its diacetate by warming it on the steam bath with 80 cc of acetic anhydride for about 2 hours. The acetic anhydride was removed on the water bath under a vacuum of about 30 mm absolute pressure. The melting point of the residue was 220°C. The residue was taken up in 100 cc of chloroform. An equal amount by weight of cyanogen bromide was added and the mixture was refluxed at about 60°C for about 5 hours. After refluxing, the mixture was washed with 100 cc of a 5% aqueous hydrochloric acid solution, dried over sodium sulfate and the chloroform removed by evaporation under a vacuum of about 30 mm. The residue had a melting point of 240°C.
The residue was then heated at about 90°C for 16 hours on a steam bath with 300 cc of 20% aqueous hydrochloric acid solution, and treated with a small amount, e.g., 1 gram of charcoal. The hydrochloric acid was then removed under a vacuum of 15 mm, the residue dissolved in 30 cc of water and precipitated by the addition of 2.4 cc of concentrated aqueous ammonia. The precipitate was filtered off and dried. It consists of 14- hydroxydihydronormorphinone. It is soluble in ethanol.
The 14-hydroxydihydronormorphinone was suspended in 200 cc of pure ethyl alcohol, half its weight of sodium bicarbonate and half its weight of allyl bromide added and the resulting mixture was refluxed at about 75°C for 48 hours. The solution was cooled, e.g., to 10°C and filtered and the alcohol removed under a vacuum of 30 mm. The residue was dissolved in chloroform and filtered. The chloroform was removed under a vacuum of 30 mm and the residue was crystallized from ethylacetate. The crystallized product, N-allyl- 1,4-hydroxydihydronormorphinone, has a melting point of 184°C, is soluble in chloroform and insoluble in petroleum ether. The yield amounts to 20% based on the weight of the reacted 14-hydroxydihydromorphinone.

brand name

Narcan (Bristol-Myers Squibb); Narcan (Endo).

Therapeutic Function

Narcotic antagonist

Biological Functions

Because of its fast onset (minutes), naloxone (Narcan) administered IV is used most frequently for the reversal of opioid overdose. However, it fails to block some side effects of the opioids that are mediated by the δ- receptor, such as hallucinations. The rapid offset of naloxone makes it necessary to administer the drug repeatedly until the opioid agonist has cleared the system to prevent relapse into overdose. The half-life of naloxone in plasma is 1 hour. It is rapidly metabolized via glucuronidation in the liver and cleared by the kidney. Naloxone given orally has a large first-pass effect, which reduces its potency significantly. Often an overshoot will follow the administration of naloxone for overdose. The heart rate and blood pressure of the patient may rise significantly. The overshoot is thought to be due to precipitation of acute withdrawal signs by naloxone. Given alone to nonaddicts, naloxone produces no pharmacological effects.
Naloxone is approved for use in neonates to reverse respiratory depression induced by maternal opioid use. In addition, naloxone has been used to improve circulation in patients in shock, an effect related to blockade of endogenous opioids. Other experimental and less well documented uses for naloxone include reversal of coma in alcohol overdose, appetite suppression, and alleviation of dementia from schizophrenia. Side effects of naloxone are minor.

General Description

Naloxone (Narcan) is a pure antagonist at allopioid receptor subtypes. Structurally, it resembles oxymorphoneexcept that the methyl group on the nitrogen isreplaced by an allyl group. This minor structural change retains high binding affinity to the receptor, but no intrinsicactivity. It is used to reverse the respiratory depressant effectsof opioid overdoses.
Naloxone is administered intravenously with an onset ofaction within 2 minutes. Because it is competing with theopioid for the receptor sites, the dose and frequency of administrationwill depend on the amount and type of narcoticbeing antagonized. Overdoses of long-acting opioids(methadone) may require multiple IV doses of naloxone orcontinuous infusions. Neonates born to opioid-exposedmothers may be given IV naloxone at birth to reverse the effectsof opiates.
Very few metabolism studies on naloxone have beenconducted, although the major metabolite found in the urineis naloxone-3-glucuronide.

Clinical Use

Naloxone has no analgesic activity. The compound is the standard antidote to treat opioid adverse reactions, opioid overdoses, or to stop an intended use of an opioid compound. Typical indications are inhibition of opioid-induced respiratory depression, termination of opioid anesthesia or protection of neonates following opioid treatment during labor. Naloxone has a short duration of action and repetitive administration may be necessary to antagonize longer acting agonists. To avoid parenteral misuse of nonscheduled oral opioid formulations (tilidine, pentazcocine), a small amount of naloxone is added which is orally inactivated, but is fully active after parenteral administration.
Naloxone is orally inactive and is only used parenterally in single or repetitive doses of 0.4– 2 mg up to a total dose of 10 mg, as an intravenous bolus injection or by infusion. The compound is more potent against pure opioid agonists than against mixed agonist – antagonists. Caution should be used in opioid-dependent persons or in persons under high-dose opioid treatment, as naloxone may precipitate an acute withdrawal reaction. Naloxone is relatively free of side effects. Nausea, vomiting, and convulsions have occasionally been reported.

Synthesis

Naloxone, (-)-17-(allyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one (3.1.92), is synthesized by the alkylation of 14-hydroxydihydronormorphinane (3.1.82) by allylbromide [55¨C58].

Naloxone Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Naloxone Suppliers

Sinopharm Chemical Reagent Co,Ltd.
Tel
86-21-63210123
Fax
86-21-63290778 86-21-63218885
Email
sj_scrc@sinopharm.com
Country
China
ProdList
9823
Advantage
79
Shanghai Fuhe Chemistry Technology Co., Ltd.
Tel
0086-21-67651709
Fax
0086-21-67651705
Email
cfx759@hotmail.com
Country
China
ProdList
410
Advantage
57
Artis Chemistry (Shanghai) Co. Ltd.
Tel
86-21-60936353
Fax
86-21-60936352
Country
China
ProdList
336
Advantage
58
Shanghai T&W Pharmaceutical Co., Ltd.
Tel
+86 21 61551611
Fax
+86 21 50676805
Country
China
ProdList
9901
Advantage
58
Shanghai TaoSu Biochemical Technology Co., Ltd.
Tel
021-33632979
Fax
021-34692979
Email
info@tsbiochem.com
Country
China
ProdList
8073
Advantage
58
Hainan Manfangyuan Pharmaceutical Chemical Co., Ltd.
Tel
0898-66518050 13307521111
Fax
+86 (898) 6677-5768
Email
mfy001@hnmfy.com
Country
China
ProdList
85
Advantage
60
Shanghai Macklin Biochemical Co.,Ltd.
Tel
15221275939 15221275939
Fax
021-50706099
Email
shenlinxing@macklin.cn
Country
China
ProdList
15873
Advantage
55
Chizhou Kailong Import and Export Trade Co., Ltd.
Tel
Fax
-
Email
xg01_gj@163.com
Country
China
ProdList
9503
Advantage
50
Sigma-Aldrich
Tel
021-61415566 800-8193336
Email
orderCN@merckgroup.com
Country
China
ProdList
51471
Advantage
80
Pharmacodia (Beijing) Co.,Ltd
Tel
+86-400-851-9921
Fax
+86-10-82826195
Email
sales@pharmacodia.com
Country
China
ProdList
2317
Advantage
55
More
Less

View Lastest Price from Naloxone manufacturers

Dideu Industries Group Limited
Product
Naloxone 465-65-6
Price
US $1.10/g
Min. Order
1g
Purity
0.999
Supply Ability
100 Tons min
Release date
2021-08-13

465-65-6, NaloxoneRelated Search:


  • 12-allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4ah-8,9c-iminoethanophenanthro(4,5
  • 12-allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4ah-8,9c-iminoethanophenanthro[4,5
  • 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-morphinan-6-on
  • 17-allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one
  • 17-allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
  • 1-n-allyl-14-hydroxynordihydromorphinone
  • 1-n-allyl-7,8-dihydro-14-hydroxynormorphinone
  • 4,5-alpha-epoxy-3,14-dihydroxy-17-(2-propenyl)-morphinan-6-on
  • 5-epoxy-3,14-dihydroxy-17-(2-propenyl)-(5alpha)-morphinan-6-on
  • -bcd)furanone
  • -bcd]furan-5(6h)-one
  • l-n-allyl-14-hydroxynordihydromorphinone
  • l-n-allyl-7,8-dihydro-14-hydroxynormorphinone
  • l-naloxone
  • n-allyl-noroxymorphone
  • 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one
  • 9: PN: WO03037310 FIGURE: 4 claimed sequence
  • Morphinan-6-one, 17-allyl-4,5a-epoxy-3,14-dihydroxy- (8CI)
  • Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5a)- (9CI)
  • Normorphinone, N-allyl-7,8-dihydro-14-hydroxy- (7CI)
  • NSC 70413
  • (5alpha)-3,14-Dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one
  • (4R)-6,10aβ-Dihydroxy-11-allyl-4α,5-epoxy-10β,4aβ-(epiminoethano)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-3-one
  • 17-Allyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
  • C07252
  • Naloxone (125 mg)
  • Methanol (test Naloxone, 1.0 mg/mL)
  • Naloxone Base
  • Morphinan-6-one,4,5-epoxy-3,14-dihydroxy-17-(2-propen-1-yl)-, (5a)-
  • Naloxone solution
  • (5α)-4,5-Epoxy-3,14-dihydroxy-17-(2-propen-1-yl)morphinan-6-one
  • Naloxone impurity
  • Naloxone, (controlled)
  • Nafoxone Hydrochloride
  • NALOXONE
  • ,5-bcd)furanone
  • 12-allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4ah-8,9c-iminoethanophenanthro(4
  • Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propen-1-yl)-, (5α)-
  • Naloxone USP/EP/BP
  • Naloxone (1.0 mg/mL in Methanol)
  • Naloxone API
  • Naloxone (1453005)
  • 465-65-6
  • Isotopically Labeled Pharmaceutical Reference Standard
  • AMPLIMEXON